Literature DB >> 24925201

False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer.

Anya Litvak1, Andrea Cercek1, Neil Segal1, Diane Reidy-Lagunes1, Zsofia K Stadler1, Rona D Yaeger1, Nancy E Kemeny1, Martin R Weiser1, Melissa S Pessin1, Leonard Saltz1.   

Abstract

Routine monitoring of carcinoembryonic antigen (CEA) levels is standard in patients with resected colorectal cancer (CRC). The incidence of false-positives and the upper limits of false-positive elevations have not been previously well characterized. A search of medical records at Memorial Sloan-Kettering Cancer Center identified 728 patients who underwent an R0 resection of locoregional CRC between January 2003 and December 2012 and who had an increase in CEA level above the normal range after a normal perioperative CEA level. Of these, 358 had a false-positive elevation of CEA level, 335 had a true-positive elevation indicative of recurrent CRC, and 35 had a true-positive elevation indicative of the development of a new, non-CRC malignancy. Of those with false elevations, 111 had a single isolated CEA level elevation (median highest CEA level of 5.5 ng/mL) with no further abnormal measurements, whereas 247 had elevations on 2 or more readings, with a median highest level of 6.7 ng/mL. Of these 247 patients with confirmed false-positive CEA level elevations, only 5 (2%) had measurements greater than 15 ng/mL, and no confirmed elevation greater than 35 ng/mL was a false-positive. False-positive CEA test results in the range of 5 to 15 ng/mL are common. Confirmation of CEA elevation in this range before initiating imaging studies may be appropriate. False-positive results greater than 15 ng/mL are rare, and all confirmed CEA levels greater than 35 ng/mL were associated with cancer recurrence.
Copyright © 2014 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24925201     DOI: 10.6004/jnccn.2014.0085

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  33 in total

1.  Clinical Applications of Liquid Biopsies in Gastrointestinal Oncology.

Authors:  Anastasia Katsiampoura; Scott Kopetz
Journal:  Gastrointest Cancer Res       Date:  2014-09

2.  Colorectal Cancer: Postoperative Follow-up and Surveillance.

Authors:  Satyajit Godhi; Ashok Godhi; Ravishankar Bhat; Sundeep Saluja
Journal:  Indian J Surg       Date:  2017-03-10       Impact factor: 0.656

Review 3.  Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?

Authors:  Mahendra Naidoo; Oliver Piercey; Jeanne Tie
Journal:  Curr Oncol Rep       Date:  2021-11-04       Impact factor: 5.075

4.  Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer.

Authors:  Raja R Narayan; Debra A Goldman; Mithat Gonen; Jonathan Reichel; Kety H Huberman; Sandeep Raj; Agnes Viale; Nancy E Kemeny; Peter J Allen; Vinod P Balachandran; Michael I D'Angelica; Ronald P DeMatteo; Jeffrey A Drebin; William R Jarnagin; T Peter Kingham
Journal:  Ann Surg Oncol       Date:  2019-01-31       Impact factor: 5.344

Review 5.  Surveillance and Survivorship after Treatment for Colon Cancer.

Authors:  Rami Makhoul; Suraj Alva; Kirsten B Wilkins
Journal:  Clin Colon Rectal Surg       Date:  2015-12

6.  The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real?

Authors:  Ryan M Thomas; Christian Jobin
Journal:  Trends Cancer       Date:  2015-09-01

7.  Association of perioperative serum carcinoembryonic antigen level and recurrence in low-risk stage IIA colon cancer.

Authors:  Han-Gil Kim; Seung Yoon Yang; Yoon Dae Han; Min Soo Cho; Byung Soh Min; Kang Young Lee; Nam Kyu Kim; Hyuk Hur
Journal:  PLoS One       Date:  2021-06-09       Impact factor: 3.240

8.  Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome.

Authors:  Tsuyoshi Konishi; Yoshifumi Shimada; Meier Hsu; Lauren Tufts; Rosa Jimenez-Rodriguez; Andrea Cercek; Rona Yaeger; Leonard Saltz; J Joshua Smith; Garrett M Nash; José G Guillem; Philip B Paty; Julio Garcia-Aguilar; Mithat Gonen; Martin R Weiser
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

9.  The best protection is early detection: Fostering timely and accurate screening.

Authors:  Aila Akosua Kattner
Journal:  Biomed J       Date:  2022-01-15       Impact factor: 7.892

10.  Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.

Authors:  Fotios Loupakis; Shruti Sharma; Madiha Derouazi; Sabina Murgioni; Paola Biason; Mario Domenico Rizzato; Cosimo Rasola; Derrick Renner; Svetlana Shchegrova; Allyson Koyen Malashevich; Meenakshi Malhotra; Himanshu Sethi; Bernhard G Zimmermann; Alexey Aleshin; Solomon Moshkevich; Paul R Billings; Jonathon D Sedgwick; Marta Schirripa; Giada Munari; Umberto Cillo; Pierluigi Pilati; Angelo Paolo Dei Tos; Vittorina Zagonel; Sara Lonardi; Matteo Fassan
Journal:  JCO Precis Oncol       Date:  2021-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.